PrimeCell Partners with Regeneration Technologies to Co-Develop Stem Cell Product
Complete the form below to unlock access to ALL audio articles.
PrimeCell™ Therapeutics LLC has announced an agreement with Regeneration Technologies, Inc. (RTI) to pursue orthopedic applications using PrimeCell™ Therapeutics' germ cell reprogramming technology.
The two companies will develop and evaluate a protocol for utilizing reprogrammed germ line stem cells in conjunction with biological implants for potentially increased therapeutic value of orthopedic grafts.
The research will focus on the use of stem cells isolated from donated material, mixed with Demineralized Bone Matrix (DBM) - working toward future research to address their reintroduction into the body of an orthopedic patient.
Future studies could include other clinical applications that would represent additional viable markets for this type of technology.
"This is a huge step forward in our pursuit of progressing research from the lab to the clinic in a timely manner in order to provide patients with effective stem cell-based therapies," said Thomas C.K. Yuen, PrimeCell Therapeutics chairman and CEO.
"Regeneration Technologies is a leader in developing innovative, healing solutions. We're excited to partner with such an innovative company."
"PrimeCell technology is an exciting and novel step forward in the area of stem cell science and regenerative medicine," said Brian K. Hutchison, RTI's Chairman, President and CEO.
"The possibilities are intriguing and promising. This should be an exciting partnership for both organizations and, even more, for those most likely to benefit from our work."
